No Data
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Selected Announcement | Alibaba increased its shareholding in Xiaopeng autos by 24.66 million shares in the third quarter; Lenovo Group's mid-term revenue increased by 22% to $33.297 billion year-on-year.
In the first ten months, Ping An Insurance's original premium revenue exceeded 740 billion yuan; net income for Netease in the third quarter was 26.2 billion yuan, with net income from games and related value-added services at 20.9 billion yuan.
3SBio's Mandi Shines in 2024 Double 11 Sales
3SBio CFO Boosts Shareholding, Confident in Future
The chief financial officer of 3sbio, He Xiang, increased his shareholding by a total of 3 million shares.
Gelonghui, November 14th | 3sbio (01530.HK) announced that it recently received a report from the company's chief financial officer, Mr. He Xiang, stating that from January 1, 2024, to the date of this announcement, he has cumulatively increased his shareholding in the company by purchasing a total of 3 million ordinary shares through centralized bidding at an average price of approximately HKD 5.99 per share, accounting for about 0.12% of the total issued shares. Mr. He indicated to the board of directors that he believes the shares are undervalued in the long term and, based on his long-term confidence in the company's business and prospects, he will consider increasing his shareholding further depending on market conditions and subject to applicable laws and regulatory provisions.
No Data
No Data